Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.
Gritstone bio has raised $32.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2024.
Gritstone bio's investors include Lilly Asia Ventures, Gilead Sciences, Redmile Group, The Column Group, Frazier Healthcare Partners.
Gritstone bio is headquartered in Emeryville, United States.
Gritstone bio is a biotechnology company that develops immunotherapies for cancer and infectious diseases.
Gritstone bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Gritstone bio — Funding & Investors." VCBacked, April 1, 2024, https://www.vcbacked.co/company/gritstone-bio. Accessed September 30, 2026.
VCBacked. (2024). Gritstone bio — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/gritstone-bio
{{cite web |title=Gritstone bio — Funding & Investors |url=https://www.vcbacked.co/company/gritstone-bio |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated